Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies - ScienceDirect
直冲最前沿，本土药械企业与跨国公司“优势互补”
KRAS G12C Inhibitor | Jacobio Pharma
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies - ScienceDirect
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies - ScienceDirect
从众星捧月到大厂退货，明星靶点“SHP2”这一年- OFweek医疗科技网
医药魔方
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies - ScienceDirect
Structure of the candidates SHP2 inhibitor. (a) HER222 (P= 1.11 x... | Download Scientific Diagram
IJMS | Free Full-Text | Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
Small‐Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview - Mitra - 2021 - ChemMedChem - Wiley Online Library
Jacobio Earns $20M AbbVie Milestone | Contract Pharma
:%0A%0AJAB-3312%20for%20Solid%20Tumors,%20Adult.png?md=1 "JAB-3312 for Solid Tumors, Adult Clinical Trial 2023 | Power")
JAB-3312 for Solid Tumors, Adult Clinical Trial 2023 | Power
加科思-B：将于2022年ESMO ASIA公布JAB-21822与JAB-3312联合用药临床前研究成果|界面新闻
美银证券盘点全球SHP2研发现状，称加科思为全球黑马| 会员动态_生物_医药_写意
Jacobio Debuts on Hong Kong Stock Exchange
加科思-B(01167)$ 美银证券盘点全球SHP2研发现状，称加科思为全球黑马2023-03-02 18:37美银...
安进带火的KRAS 抑制剂JAB-3312 在中国的临床申请获得承办
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies - ScienceDirect
KRAS抑制剂战火纷飞，大小公司各显神通
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond - Cancer Treatment Reviews
安进KRAS 突变抑制剂AMG 510 国内获批临床-Insight数据库
